



Biotech Daily

Wednesday March 25, 2009

Daily news on ASX-listed biotechnology companies

*** BIOPHARMICA CHARACTERIZES PROTEIN EXPRESSION**

BIOPHARMICA

Biopharmica's subsidiary Molecular Discovery Systems has conducted a protein characterization contract for the Lung Institute of Western Australia.

Biopharmica said its wholly-owned subsidiary characterized the expression of five proteins in human lung and mesothelioma cancer cells as well as their response to treatment.

The project was undertaken for the institute's Prof Kanti Bhoola and the company said that with the first phase of the project "nearing completion with highly satisfactory results" and preparation had begun for the next phase of the project, 'The effect of Bradykinin on mitogenesis'.

Biopharmica said the expression of five proteins within lung and mesothelioma cancer cells, as well as their response to treatment was required to support previous findings within Prof Bhoola's research program.

Image capture and analysis of the prepared plates was conducted at the Molecular Discovery Systems laboratory to provide the result of analysis documents detailing protein location and abundance.

Biopharmica said that as a result of the work, interest had been generated in other potential applications of the Incell Analyser 1000 for research purposes.

Molecular Discovery Systems and the Lung Institute of Western Australia are negotiating the incorporation of the analysis technology into other research programs.

Biopharmica said the Molecular Discovery Systems-owned Incell Analyser 1000 combined high resolution imaging and high-content analysis to provide a technology that "rapidly detects and quantifies components of the cell much faster than conventional methods".

The company said Molecular Discovery Systems was available for contract work and more details were at: <http://biopharmica.com.au/portfolio/mds/index.html>

Biopharmica was unchanged at 3.5 cents.